1. |
Potential therapeutic interventions for hyperglycaemia |
|
Inpharma Weekly,
Volume &NA;,
Issue 1367,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
New approaches considered for bacterial infections |
|
Inpharma Weekly,
Volume &NA;,
Issue 1367,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
Loratadine OTC switch approved, cost saving in the US |
|
Inpharma Weekly,
Volume &NA;,
Issue 1367,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
Lopinavir/ritonavir long-term therapy good value for treatment-naive patients |
|
Inpharma Weekly,
Volume &NA;,
Issue 1367,
2002,
Page 5-5
L Hunt,
Preview
|
|
摘要:
The short duration of antiretroviral drug regimen clinical trials does not allow for long-term economic and quality-of-life (QOL) evaluations of the various competing antiretroviral regimens. However, estimates of long-term outcome and cost differences can be obtained from a long-term model using surrogate marker data obtained from antiretroviral clinical trials, incorporating epidemiological and economic data, and data on current patterns of treatment. A team of investigators from the Medical University of South Carolina, Charleston, and Abbott Laboratories, Illinois, US, constructed a model to assess the long-term health outcomes and lifetime cost effectiveness of the fixed combination antiretroviral agent lopinavir/ritonavir, compared with nelfinavir, in treatment-naive patients. The results of the study were presented at the 5th Annual Congress of the International Society for Pharmacoeconomics and Outcomes Research, held in Rotterdam, The Netherlands, in November.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Asthma self-management good value in The Netherlands |
|
Inpharma Weekly,
Volume &NA;,
Issue 1367,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
D 003: antiplatelet and cholesterol-lowering effects |
|
Inpharma Weekly,
Volume &NA;,
Issue 1367,
2002,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
IL-18 attenuates GVHD, maintains GVL activity in mice |
|
Inpharma Weekly,
Volume &NA;,
Issue 1367,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
Adalimumab improves symptoms and QOL in rheumatoid arthritis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1367,
2002,
Page 9-11
RM Poole,
Preview
|
|
摘要:
The anti-tumour necrosis factor (TNF)-α monoclonal antibody adalimumab [D2E7; 'Humira'] provides durable improvement in symptoms and quality of life (QOL) in patients with rheumatoid arthritis (RA), according to several studies presented at the 66th Annual Scientific Meeting of the American College of Rheumatology (ACR) [New Orleans, US; October 2002]. Two pivotal phase III studies showed that adalimumab, alone or in combination with patients' existing therapy, provided significant improvements in symptoms and QOL for patients who had not responded adequately to methotrexate and/or other disease-modifying antirheumatic drugs (DMARDs). One of these studies also showed that leflunomide, in combination with methotrexate, inhibited the progression of joint damage. Two long-term studies presented at the meeting demonstrated the durability of the improvements in symptoms achieved with adalimumab. Adalimumab was well tolerated in these studies and in a 24-week safety study presented at the meeting, which showed that its use in combination with standard medications for RA did not increase the incidence of adverse events.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
ZYC3: ER-independent neuroprotection, vasoactivity in rats |
|
Inpharma Weekly,
Volume &NA;,
Issue 1367,
2002,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
CYP2C19 genotype predicts lansoprazole response in GORD |
|
Inpharma Weekly,
Volume &NA;,
Issue 1367,
2002,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|